{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-062656","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2024-05-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.568879+00:00","generated_at":"2026-06-01T11:21:56.099719+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA clears IND for SAB Biotherapeutics' T1D therapy SAB-142 Phase 1 trial","bullets":["FDA cleared IND for SAB-142, a human anti-thymocyte immunoglobulin for type 1 diabetes.","Phase 1 HUMAN trial is randomized, double-blind, placebo-controlled, single-ascending dose (0.03-2.5 mg/kg).","Enrollment of US patients with type 1 diabetes now permitted; third cohort dosed with no serum sickness.","Topline results from the MELD-ATG study expected in 2025.","SAB-142 aims to delay onset or progression of stage 3 type 1 diabetes."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-062656","json":"https://secwatch.observer/filing/0000950170-24-062656.json","markdown":"https://secwatch.observer/filing/0000950170-24-062656.md","text":"https://secwatch.observer/filing/0000950170-24-062656.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024062656/0000950170-24-062656-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024062656/sabs-20240521.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T11:21:56.099719+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}